AMLX vs CRNX: How Amylyx Pharmaceuticals and Crinetics Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMLX and CRNX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMLX and CRNX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Its lead program is avexitide, a GLP-1 antagonist being tested in adults with post-bariatric hypoglycemia (PBH), a condition where people who have had Roux-en-Y gastric bypass surgery experience severe blood-sugar crashes. The pivotal Phase 3 LUCIDITY trial enrolled 78 participants across a 16-week blinded period, completed its final participant visit in mid-2026, and reads out topline in late August or early September 2026. Behind it sit AMX0035 in Wolfram syndrome (a focused pivotal Phase 3 was guided for the second half of 2026 after extended Phase 2 HELIOS data showed trends in pancreatic function and vision stabilization), AMX0114 in ALS (Phase 1 LUMINA data reported as safety-supportive), and AMX0318 in IND-enabling studies.

Full AMLX guide

Crinetics Pharmaceuticals is a San Diego-based biopharmaceutical company that discovers and develops oral small-molecule therapies for endocrine diseases and endocrine-related tumors. Its first marketed product, PALSONIFY (paltusotine), is a non-peptide, once-daily oral selective somatostatin receptor ligand approved by the FDA in September 2025 and by European regulators in 2026 for acromegaly, a condition long treated with monthly injectable drugs. Behind PALSONIFY sits a deep pipeline of 10-plus programs, led by atumelnant (in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome) and CRN09682, a drug conjugate aimed at neuroendocrine tumors, plus earlier programs across Graves' disease, hyperparathyroidism, polycystic kidney disease, and other endocrine indications.

Full CRNX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMLX drivers: The LUCIDITY Phase 3 readout; A market with no approved therapy.
• CRNX drivers: Pending Vertex acquisition at $85 cash; PALSONIFY commercial launch.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. For CRNX, the dominant risk is deal risk: the Vertex acquisition still requires Crinetics shareholder approval, antitrust and other regulatory clearances, and satisfaction of customary closing conditions, and if it fails the stock could fall back toward its pre-announcement level near the $45 to $55 range implied by a roughly $4.5 billion market cap.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMLX if you believe its drivers more; CRNX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMLX and CRNX guides.

AMLX. Standard valuation multiples do not apply here because there is no revenue and no path to profitability without an approval. The market is pricing a probability of avexitide reaching the market against a fully funded cost base, which is why the roughly $2 billion capitalization sits on top of about $250 million of cash and an annualized loss near $170 million. Watch the cash line and the runway guidance each quarter, because that is what determines whether Amylyx negotiates a post-readout financing from strength or from need.

CRNX. Before the July 2026 acquisition announcement, Crinetics carried a market capitalization of roughly $4.5 billion despite minimal revenue, a valuation typical of a rare-disease biotech pricing in an early launch and pipeline optionality. The Vertex offer of $85.00 per share, about $10 billion in equity value, reset the stock to trade near that cash price. Standard earnings multiples are not meaningful here given the company runs a large net loss funded by its cash balance.

Headline figures (approximate, August 2026): AMLX shows product revenue None (Relyvrio withdrawn in 2024), cash and equivalents ~$250.8M (June 30, 2026), cash runway Guided into 2028, r&d expense (h1 2026) ~$51.4M; CRNX shows acquisition price (vertex, cash) ~$85.00/share, deal equity value ~$10B, revenue (q1 2026) ~$10.7M, palsonify net product sales (q1 2026) ~$10.3M.

AMLX and CRNX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMLX and CRNX exposure against your real portfolio. It is not an investment adviser.